Evaluation of PSMA target diagnostic PET tracers for therapeutic monitoring of [177Lu]ludotadipep of prostate cancer: Screening of PSMA target efficiency and biodistribution using [18F]DCFPyL and [68Ga]PSMA-11
Biochemical and Biophysical Research Communications · 2023
DOI: 10.1016/j.bbrc.2023.02.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Min Hwan Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Radiopharmaceuticals, FutureChem Co. Ltd, Seoul, 04793, Republic of Korea. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Ministry of Science, ICT and Future Planning, Korea Institute of Radiological and Medical Sciences.
Abstract (Originalsprache)
We have compared the similarity of the in vivo distribution of the prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agents [18F]DCFPyL, [68Ga]galdotadipep, and [68Ga]PSMA-11. This study is designed for a further selection of a PSMA-targeted PET imaging agent for the therapeutic evaluation of [177Lu]ludotadipep, our previously developed prostate-specific membrane antigen (PSMA)-targeted prostate cancer therapeutic radiopharmaceutical. In vitro cell uptake was performed to evaluate the affinity to PSMA using PSMA + PC3-PIP, and PSMA- PC3-flu was used for the study. MicroPET/CT 60 min dynamic imaging and biodistribution were performed at 1, 2, and 4 h after injection. Autoradiography and immunohistochemistry were performed to evaluate the PSMA + tumor target efficiency. In the microPET/CT image, [68Ga]PSMA-11 showed the highest uptake in the kidney among all three compounds. [18F]DCFPyL and [68Ga]PSMA-11 showed similar patterns of in vivo biodistribution and high tumor targeting efficiency, similar to those of[68Ga]galdotadipep. All three agents showed high uptake in tumor tissue on autoradiography, and PSMA expression was confirmed by immunohistochemistry. Thus, [18F]DCFPyL or [68Ga]PSMA-11 can be used as a PET imaging agent to monitor [177Lu]ludotadipep therapy in prostate cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute of Radiopharmaceuticals, FutureChem Co. Ltd, Seoul, 04793, Republic of Korea.
- Division of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul, 01812, Republic of Korea.
- Research Institute of Radiopharmaceuticals, FutureChem Co. Ltd, Seoul, 04793, Republic of Korea. Electronic address: daeyoon.chi@futurechem.co.kr.
Förderung
- Ministry of Science, ICT and Future Planning
- Korea Institute of Radiological and Medical Sciences
Zitieren
APA
Kim, M. H., Lee, K., Oh, K., Kim, C. H., Kil, H. S., Lee, Y. J., Lee, K. C., & Chi, D. Y. (2023). Evaluation of PSMA target diagnostic PET tracers for therapeutic monitoring of [177Lu]ludotadipep of prostate cancer: Screening of PSMA target efficiency and biodistribution using [18F]DCFPyL and [68Ga]PSMA-11. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.02.003
Vancouver
Kim MH, Lee K, Oh K, Kim CH, Kil HS, Lee YJ, et al. Evaluation of PSMA target diagnostic PET tracers for therapeutic monitoring of [177Lu]ludotadipep of prostate cancer: Screening of PSMA target efficiency and biodistribution using [18F]DCFPyL and [68Ga]PSMA-11. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.02.003
BibTeX
@article{Kim2023,
author = {Kim, Min Hwan and Lee, Kyongkyu and Oh, Keumrok and Kim, Chul Hee and Kil, Hee Seup and Lee, Yong Jin and Lee, Kyo Chul and Chi, Dae Yoon},
title = {Evaluation of PSMA target diagnostic PET tracers for therapeutic monitoring of [177Lu]ludotadipep of prostate cancer: Screening of PSMA target efficiency and biodistribution using [18F]DCFPyL and [68Ga]PSMA-11},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
doi = {10.1016/j.bbrc.2023.02.003}
}
EUVIMED